Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis

dc.contributorHáskóli Íslandsen_US
dc.contributorUniversity of Icelanden_US
dc.contributor.authorWesterlind, Helga
dc.contributor.authorRönnelid, Johan
dc.contributor.authorHansson, Monika
dc.contributor.authorAlfredsson, Lars
dc.contributor.authorMathsson‐Alm, Linda
dc.contributor.authorSerre, Guy
dc.contributor.authorCornillet, Martin
dc.contributor.authorHolmdahl, Rikard
dc.contributor.authorJakobsson, Per‐Johan
dc.contributor.authorSkriner, Karl
dc.contributor.authorKlareskog, Lars
dc.contributor.authorSaevarsdottir, Saedis
dc.contributor.authorAskling, Johan
dc.contributor.departmentLæknadeild (HÍ)en_US
dc.contributor.departmentFaculty of Medicine (UI)en_US
dc.contributor.schoolHeilbrigðisvísindasvið (HÍ)en_US
dc.contributor.schoolSchool of Health Sciences (UI)en_US
dc.date.accessioned2020-11-06T16:04:53Z
dc.date.available2020-11-06T16:04:53Z
dc.date.issued2020-09-07
dc.descriptionPublisher's version (útgefin grein)en_US
dc.description.abstractObjective: To investigate the relationship between anti–citrullinated protein antibodies (ACPAs), specific ACPA subspecificities, rheumatoid factor (RF) isotypes, and incident cardiovascular (CV) events in patients with rheumatoid arthritis (RA). Methods: Serum samples from Swedish patients with new-onset RA (diagnosed within 1 year of symptom onset between 1996 and 2009) were centrally typed for anti–cyclic citrullinated peptide 2 (anti-CCP2) antibodies, 20 ACPA subspecificities, and RF isotypes. Patients were followed up longitudinally in nationwide registers to monitor the occurrence of acute coronary syndrome (ACS), stroke, CV-related death, and major adverse CV events (MACE). The association between each serologic marker and CV outcome, and the impact of adjustment for the Disease Activity Score in 28 joints (DAS28), smoking status, and income at baseline, were assessed using Cox proportional hazards models. In addition, associations of serologic markers with all-cause mortality were explored. Results: In total, 2,814 patients with RA were included in the study. The median follow-up was 13 years, during which the CV end points of ACS, stroke, or CV-related death were reported to occur in 375 patients. Occurrence and/or levels of anti-CCP2 were associated with risk of incident ACS (hazard ratio [HR] 1.46, 95% confidence interval [95% CI] 1.03–2.06), stroke (HR 1.47, 95% CI 1.03–2.10), CV-related death (P = 0.024 for association with anti-CCP2 levels), and MACE (HR 1.34, 95% CI 1.06–1.70). Similarly, an association with the number of ACPA subspecificities was observed; however, this could not be attributed to any individual or group of ACPA subspecificities. Presence of IgM-RF was associated with all CV end points except ACS, and IgA-RF was exclusively associated with CV-related death. Adjustment for smoking status, income, and DAS28 scores decreased most of the HRs, whereas IgA-RF remained associated with CV-related death (HR 1.61, 95% CI 1.05–2.48). All of the assessed serologic makers were associated with all-cause mortality. Conclusion: RF isotypes and ACPAs are associated with future CV events in patients with RA. ACPA levels and number of subspecificities seem more important than the occurrence of particular subspecificities, and these associations were not explained by a history of ever smoking.en_US
dc.description.sponsorshipKarolinska institutet (strategic research area epidemiology), The nordic research council (nordforsk), The rheumatology research foundation (foreum), Stiftelsen för Strategisk Forskning, Vetenskapsrådet, Stockholms Läns Landsting, The swedish heart lung foundationen_US
dc.description.versionPeer Revieweden_US
dc.format.extent1658-1667en_US
dc.identifier.citationWesterlind, H., Rönnelid, J., Hansson, M., Alfredsson, L., Mathsson‐Alm, L., Serre, G., Cornillet, M., Holmdahl, R., Jakobsson, P.‐J., Skriner, K., Klareskog, L., Saevarsdottir, S. and Askling, J. (2020), Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, 72: 1658-1667. doi:10.1002/art.41381en_US
dc.identifier.doi10.1002/art.41381
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205 (eISSN)
dc.identifier.journalArthritis & Rheumatologyen_US
dc.identifier.urihttps://hdl.handle.net/20.500.11815/2179
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofseriesArthritis & Rheumatology;72(10)
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/10.1002/art.41381en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectCardiovascular diseaseen_US
dc.subjectIktsýkien_US
dc.subjectKransæðasjúkdómaren_US
dc.titleAnti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritisen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dcterms.licenseThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.en_US

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Hleð...
Thumbnail Image
Nafn:
art.41381.pdf
Stærð:
286.51 KB
Snið:
Adobe Portable Document Format
Description:
Publisher´s version

Undirflokkur